Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies

Author(s): Karen Ekkelund Petersen, Günaj Rakipovski, Kirsten Raun, Jens Lykkesfeldt.

Journal Name: Current Diabetes Reviews

Volume 12 , Issue 4 , 2016

Become EABM
Become Reviewer


Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.

Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [331 - 358]
Pages: 28
DOI: 10.2174/1573399812666150918150608

Article Metrics

PDF: 20